Detailed dose evidence documented for Daptomycin in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
cSSSI: 4 mg/kg IV QD for 7-14 days. S. aureus bacteremia/right-sided IE: 6 mg/kg IV QD. Pediatric (1-17 y): age-dependent (10 mg/kg for 1 to less than 2 y; 9 mg/kg for 2-6 y; 7 mg/kg for 7-11 y; 5 mg/kg for 12-17 y for cSSSI; higher for bacteremia). Administer IV over 30 min (adults) or 30-60 min (pediatric). No dose adjustment needed for mild-moderate hepatic impairment.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
Higher doses (8-12 mg/kg) studied in some settings (e.g., IE, VRE) but not FDA-approved; associated with increased CPK elevation risk.
Not established
What is not established
Pneumonia (not indicated — inactivated by surfactant).
Left-sided infective endocarditis (not indicated; poor outcomes in trial).
Prosthetic valve endocarditis (not studied).
Pediatric patients less than 1 year: not recommended based on animal toxicity studies; risks of muscular, neuromuscular, and nervous system effects outweigh potential benefit.